not only stop malignancies in a number of solid tumor cancers, but also to beat a much-used but faulted chemotherapy, gemcitabine, known by its trade name Gemzar, an Eli Lilly & Co. (NYSE:LLY) offering for cancers of the lung, pancreas, bladder and breast, that has since gone generic.
Data is impressive: taking mice that had been pre-conditioned to grow tumors from human cancer cells, Rexahn's lead product RX-3117 was applied to nine cancerous conditions including colon, lung, pancreas, kidney and cervix. Gemcitabine failed to inhibit tumor growth, from a statistically significant zero to 30%. RX-3117 halted tumor growth from 62% to an astounding 100%. Clear from the study, on a one-to-one comparison, Rexahn's drug has so far proven superior, and animals did not suffer a loss of body weight, suggesting low toxicity. ..... "
News 
Market Data 
Discover 
AI
